<?xml version='1.0' encoding='utf-8'?>
<document id="28169935"><sentence text="Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues." /><sentence text="Drug-drug interactions with insulin secretagogues are associated with increased risk of serious hypoglycemia in patients with type 2 diabetes" /><sentence text=" We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia"><entity charOffset="117-126" id="DDI-PubMed.28169935.s3.e0" text="glyburide" /><entity charOffset="128-139" id="DDI-PubMed.28169935.s3.e1" text="glimepiride" /><entity charOffset="141-152" id="DDI-PubMed.28169935.s3.e2" text="repaglinide" /><entity charOffset="158-169" id="DDI-PubMed.28169935.s3.e3" text="nateglinide" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e0" e2="DDI-PubMed.28169935.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e0" e2="DDI-PubMed.28169935.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e0" e2="DDI-PubMed.28169935.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e0" e2="DDI-PubMed.28169935.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e1" e2="DDI-PubMed.28169935.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e1" e2="DDI-PubMed.28169935.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e1" e2="DDI-PubMed.28169935.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e2" e2="DDI-PubMed.28169935.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28169935.s3.e2" e2="DDI-PubMed.28169935.s3.e3" /></sentence><sentence text="" /><sentence text="We screened 400 drugs frequently coprescribed with the secretagogues as candidate interacting precipitants" /><sentence text=" We first predicted the drug-drug interaction potential based on the pharmacokinetics of each secretagogue-precipitant pair" /><sentence text=" We then performed pharmacoepidemiologic screening for each secretagogue of interest, and for metformin as a negative control, using an administrative claims database and the self-controlled case series design"><entity charOffset="94-103" id="DDI-PubMed.28169935.s7.e0" text="metformin" /></sentence><sentence text=" The overall rate ratios (RRs) and those for four predefined risk periods were estimated using Poisson regression" /><sentence text=" The RRs were adjusted for multiple estimation using semi-Bayes method, and then adjusted for metformin results to distinguish native effects of the precipitant from a drug-drug interaction"><entity charOffset="94-103" id="DDI-PubMed.28169935.s9.e0" text="metformin" /></sentence><sentence text="" /><sentence text="We predicted 34 pharmacokinetic drug-drug interactions with the secretagogues, nine moderate and 25 weak" /><sentence text=" There were 140 and 61 secretagogue-precipitant pairs associated with increased rates of serious hypoglycemia before and after the metformin adjustment, respectively"><entity charOffset="131-140" id="DDI-PubMed.28169935.s12.e0" text="metformin" /></sentence><sentence text=" The results from pharmacokinetic prediction correlated poorly with those from pharmacoepidemiologic screening" /><sentence text="" /><sentence text="The self-controlled case series design has the potential to be widely applicable to screening for drug-drug interactions that lead to adverse outcomes identifiable in healthcare databases" /><sentence text=" Coupling pharmacokinetic prediction with pharmacoepidemiologic screening did not notably improve the ability to identify drug-drug interactions in this case" /><sentence text="" /></document>